TLR3 gene polymorphisms in cancer: a systematic review and meta-analysis

Cancer Communications

Table 4 Pooled ORs and 95 % CIs of TLR3 polymorphisms in this meta-analysis

SNP	Number of studies	M1			M2			M3			M4			Number of studies	M5
SNP	Number of studies	OR (95 % CI)	P	I ² (%)	OR (95 % CI)	P	I² (%)	OR (95 % CI)	P	I² (%)	OR (95 % CI)	P	I² (%)	Number of studies	OR (95 % CI)	P	I² (%)
rs3775290 (C13766T, C > T)	5	1.04	0.854^*	70.0	1.38	0.110	0.0	1.09	0.640^*	69.4	1.41	0.082	0.0	6	1.06	0.550	59.3
rs3775290 (C13766T, C > T)		(0.72-1.49)			(0.93-2.06)			(0.77-1.53)			(0.96-2.08)				(0.87-1.30)
rs3775291 (G13909A, L412F, G > A)	8	1.12	0.056^*	53.9	1.13	0.335^*	66.5	1.12	0.054^*	58.6	1.08	0.507^*	65.2	9	1.09	0.064^*	59.5
rs3775291 (G13909A, L412F, G > A)	8	(1.00-1.26)			(0.88-1.45)			(1.00-1.26)			(0.86-1.37)				(1.00-1.19)
rs3775292 (C/G, intron 3, C > G)	4	0.96	0.554^*	54.5	0.93	0.500	34.7	0.97	0.476	23.1	0.94	0.554	49.9	4	0.97	0.416	0.0
rs3775292 (C/G, intron 3, C > G)	4	(0.83-1.11)			(0.75-1.15)			(0.89-1.06)			(0.76-1.16)				(0.90-1.05)
rs5743312 (C9948T, intron 3, C > T)	3	1.02	0.832	0.0	1.88	<0.001	0.0	1.08	0.267	0.0	1.86	<0.001	0.0	4	1.11	0.047	7.1
rs5743312 (C9948T, intron 3, C > T)	3	(0.88-1.17)			(1.33-2.67)			(0.94-1.23)			(1.32-2.63)				(1.00-1.24)

OR, odds ratio; CI, confidence interval. ^*The heterogeneity exists; a random-effect model based on the DerSimonian and Laird method or a fixed-effect model based on the Mantel-Haenszel method was used. M1: Aa vs. AA, heterozygote comparison; M2: aa vs. AA, homozygote comparison; M3: Aa + aa vs. AA, dominant model; M4: aa vs. AA + Aa, recessive model; M5: a vs. A, allelic model (A indicates wild allele, a indicates variant allele). The bold means the significant results.

ISSN: 2523-3548